Versant Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
Other funds holding SUPN
HWAM
WCM
CNAM
ETC
YIH
SOADOR
LSERS
Versant Capital Management's SUPN Position: Q2 2026 in Review
Versant Capital Management reduced its Supernus Pharmaceuticals (SUPN) stake by 0.49% in Q2 2026, selling an estimated $240 and leaving 1,021 shares worth $47.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1395.
Versant Capital Management first reported a position in SUPN in Q3 2019 and has held it in 18 quarters since. The position peaked at $53K in Q1 2026. 50 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.
- Versant Capital Management held 1,021 shares of Supernus Pharmaceuticals worth $47.5K as of Q2 2026.
- Versant Capital Management sold 5 Supernus Pharmaceuticals shares in Q2 2026, an estimated $240.
- Supernus Pharmaceuticals made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1395 holding.
- Versant Capital Management first reported a position in Supernus Pharmaceuticals in Q3 2019 and has held it in 18 quarters since.
- Versant Capital Management's Supernus Pharmaceuticals position peaked at $53K in Q1 2026.
- 50 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.
Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.